trabectedin
Selected indexed studies
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. (N Engl J Med, 2024) [PMID:39231341]
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. (Lancet Oncol, 2022) [PMID:35835135]
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. (J Clin Oncol, 2016) [PMID:26371143]
_Worker-drafted node — pending editorial review._
Connections
trabectedin is a side effect of
Sources
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. (2022) pubmed
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. (2024) pubmed
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. (2016) pubmed
- Trabectedin in Cancers: Mechanisms and Clinical Applications. (2022) pubmed
- Trabectedin. (2009) pubmed
- Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know? (2024) pubmed
- Trabectedin therapy for sarcomas. (2010) pubmed
- Trabectedin in soft tissue sarcomas. (2014) pubmed
- Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes. (2022) pubmed
- Trabectedin in Ovarian Cancer: is it now a Standard of Care? (2018) pubmed